About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 15011 record(s)
Req # A-2023-001298
All public records regarding the establishment and purpose of the Branch Executive Committee. All individuals and departments involved and who the panel reports to. How the Branch Executive Committee's decisions are reviewed.Organization: Health Canada
October 2024
Req # A-2024-000496
The most current status of the Abbreviated New Drug Submission (ANDS) seeking approval of a generic degarelix acetate product, which was accepted into review by Health Canada in January 2024: Inactive; Process; Process Hold; Withdrawn. If the status…Organization: Health Canada
October 2024
Req # A-2024-000497
Provide a screenshot of the status page for the Degarelix Acetate Abbreviated New Drug Submission (ANDS) on the Drug Submission Tracking System (DSTS) interface.Organization: Health Canada
October 2024
Req # A-2024-000623
For the time period — October 17, 2018, to December 31, 2023 — the general companion totals to the aggregate data requested under A-2024-000151. If possible, further disaggregate the data disclosed under A-2024-000151 relating to Part 11 according…Organization: Health Canada
October 2024
Req # A-2024-000634
Number of psilocybin access requests submitted and granted since January 2022 under the Special Access Program; Number of exemption requests submitted and granted under subsection 56(1) of the Controlled Drugs and Substances Act (between 2020-2022…Organization: Health Canada
October 2024
Req # A-2019-001550
Adverse Drug Reactions (ADRs). Report numbers: E2B_02720298, E2B_02734604, E2B_02734630, & E2B_02749506.Organization: Health Canada
October 2024
Req # A-2024-000240
Adverse Drug Reactions (ADRs). Report numbers: E2B_07049790, E2B_07046471.Organization: Health Canada
October 2024
Req # A-2024-000273
Adverse Drug Reaction (ADR). Report number: E2B_06689043.Organization: Health Canada
October 2024
Req # A-2024-000374
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 24-103258-616, The Governor General’s Symposium: Building a Safe and Respectful Digital World.Organization: Health Canada
October 2024
Req # A-2024-000447
Adverse Drug Reactions (ADRs). Report numbers: E2B_07160708, E2B_07185457.Organization: Health Canada
October 2024